(19)
(11) EP 4 313 315 A1

(12)

(43) Date of publication:
07.02.2024 Bulletin 2024/06

(21) Application number: 22782201.2

(22) Date of filing: 31.03.2022
(51) International Patent Classification (IPC): 
A61P 35/00(2006.01)
A61P 1/16(2006.01)
(52) Cooperative Patent Classification (CPC):
A61P 35/00; A61P 1/16; A61K 31/7088
(86) International application number:
PCT/US2022/022801
(87) International publication number:
WO 2022/212690 (06.10.2022 Gazette 2022/40)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
KH MA MD TN

(30) Priority: 01.04.2021 US 202163169674 P
11.01.2022 US 202263298589 P

(71) Applicant: TriSalus Life Sciences, Inc.
Westminster, CO 80031 (US)

(72) Inventors:
  • KATZ, Steven, C.
    East Greenwich, RI 02818 (US)
  • COX, Bryan, F.
    Muscatine, IA 52761 (US)
  • JAROCH, David, Benjamin
    Arvada, CO 80004 (US)

(74) Representative: Goddar, Heinz J. 
Boehmert & Boehmert Anwaltspartnerschaft mbB Pettenkoferstrasse 22
80336 München
80336 München (DE)

   


(54) CANCER THERAPY USING TOLL-LIKE RECEPTOR AGONISTS